Difference between revisions of "Template:Antithrombotics"
Jump to navigation
Jump to search
blackwiki>Diannaa (improve mark-up) |
blackwiki>Funandtrvl (fx) |
||
| Line 2: | Line 2: | ||
| name = Antithrombotics | | name = Antithrombotics | ||
| title = [[Antithrombotic]]s ([[thrombolytic drug|thrombolytics]], [[anticoagulant]]s and [[antiplatelet drug]]s) ([[ATC code B01|B01]]) | | title = [[Antithrombotic]]s ([[thrombolytic drug|thrombolytics]], [[anticoagulant]]s and [[antiplatelet drug]]s) ([[ATC code B01|B01]]) | ||
| − | | | + | | bodyclass = hlist |
| − | | groupstyle = background:MistyRose; | + | | groupstyle = background:MistyRose; width:10em; |
| + | | liststyle = width:auto; | ||
| group1 = [[Antiplatelet drug]]s | | group1 = [[Antiplatelet drug]]s | ||
| list1 = {{Navbox subgroup | | list1 = {{Navbox subgroup | ||
| − | | groupstyle = background-color: MistyRose | + | | groupstyle = background-color: MistyRose; width:16em; |
| + | | liststyle = width:auto; | ||
| group1 = [[Glycoprotein IIb/IIIa inhibitors]] | | group1 = [[Glycoprotein IIb/IIIa inhibitors]] | ||
| Line 29: | Line 31: | ||
| list3 = | | list3 = | ||
* [[Beraprost]] | * [[Beraprost]] | ||
| + | * [[Iloprost]] | ||
* [[Prostacyclin]] | * [[Prostacyclin]] | ||
| − | |||
* [[Treprostinil]] | * [[Treprostinil]] | ||
| Line 46: | Line 48: | ||
** [[Dipyridamole]] | ** [[Dipyridamole]] | ||
** [[Picotamide]] | ** [[Picotamide]] | ||
| − | |||
* ''[[Thromboxane receptor antagonist|receptor antagonist]]'' | * ''[[Thromboxane receptor antagonist|receptor antagonist]]'' | ||
** [[Terutroban]]<sup>†</sup> | ** [[Terutroban]]<sup>†</sup> | ||
| Line 64: | Line 65: | ||
| group2 = [[Anticoagulant]]s | | group2 = [[Anticoagulant]]s | ||
| list2 = {{Navbox subgroup | | list2 = {{Navbox subgroup | ||
| − | | groupstyle = background-color: MistyRose | + | | groupstyle = background-color: MistyRose; width:16em; |
| + | | liststyle = width:auto; | ||
| − | | | + | | group2 = [[Vitamin K antagonist]]s<br />(inhibit [[Thrombin|II]], [[Factor VII|VII]], [[Factor IX|IX]], [[Factor X|X]]) |
| − | | | + | | list2 = |
* ''[[coumarin]]s:'' [[Acenocoumarol]] | * ''[[coumarin]]s:'' [[Acenocoumarol]] | ||
* [[Coumatetralyl]] | * [[Coumatetralyl]] | ||
| Line 74: | Line 76: | ||
* [[Phenprocoumon]] | * [[Phenprocoumon]] | ||
* [[Warfarin]]<sup>#</sup> | * [[Warfarin]]<sup>#</sup> | ||
| − | |||
*''[[1,3-Indandione]]s:'' [[Clorindione]] | *''[[1,3-Indandione]]s:'' [[Clorindione]] | ||
* [[Diphenadione]] | * [[Diphenadione]] | ||
* [[Phenindione]] | * [[Phenindione]] | ||
| − | |||
* ''other:'' [[Tioclomarol]] | * ''other:'' [[Tioclomarol]] | ||
| − | | | + | | group3 = [[Factor Xa]] inhibitors<br />(with some II inhibition) |
| − | | | + | | list3 = {{Navbox subgroup |
| groupstyle = background-color: MistyRose | | groupstyle = background-color: MistyRose | ||
| group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | | group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | ||
| list1 = | | list1 = | ||
| − | * ''[[low | + | * ''[[low molecular weight heparin]]'' |
** [[Bemiparin sodium|Bemiparin]] | ** [[Bemiparin sodium|Bemiparin]] | ||
** [[Certoparin sodium|Certoparin]] | ** [[Certoparin sodium|Certoparin]] | ||
| Line 96: | Line 96: | ||
** [[Reviparin sodium|Reviparin]] | ** [[Reviparin sodium|Reviparin]] | ||
** [[Tinzaparin sodium|Tinzaparin]] | ** [[Tinzaparin sodium|Tinzaparin]] | ||
| − | |||
* ''[[oligosaccharide]]s'' | * ''[[oligosaccharide]]s'' | ||
** [[Fondaparinux]] | ** [[Fondaparinux]] | ||
** [[Idraparinux]] | ** [[Idraparinux]] | ||
| − | |||
* ''[[heparinoid]]'' | * ''[[heparinoid]]'' | ||
** [[Danaparoid]] | ** [[Danaparoid]] | ||
| + | ** [[Dermatan sulfate]] | ||
** [[Sulodexide]] | ** [[Sulodexide]] | ||
| − | |||
| − | | | + | | group2 = [[Direct Xa inhibitor]]s |
| − | | | + | | list2 = |
* ''xabans'' | * ''xabans'' | ||
** [[Apixaban]] | ** [[Apixaban]] | ||
| Line 116: | Line 114: | ||
}} | }} | ||
| − | | | + | | group5 = [[Direct thrombin inhibitor|Direct thrombin (II) inhibitor]]s |
| − | | | + | | list5 = |
* ''[[Direct_thrombin_inhibitor#Bivalent|bivalent]]:'' [[Hirudin]] | * ''[[Direct_thrombin_inhibitor#Bivalent|bivalent]]:'' [[Hirudin]] | ||
** [[Bivalirudin]] | ** [[Bivalirudin]] | ||
| + | ** [[Desirudin]] | ||
** [[Lepirudin]] | ** [[Lepirudin]] | ||
| − | |||
| − | |||
* ''[[Direct_thrombin_inhibitor#Univalent|univalent]]:'' [[Argatroban]] | * ''[[Direct_thrombin_inhibitor#Univalent|univalent]]:'' [[Argatroban]] | ||
* [[Dabigatran]] | * [[Dabigatran]] | ||
| Line 128: | Line 125: | ||
* [[Ximelagatran]]<sup>‡</sup> | * [[Ximelagatran]]<sup>‡</sup> | ||
| − | | | + | | group6 = Other |
| − | | | + | | list6 = |
| − | * [[ | + | * [[Antithrombin|Antithrombin III]] |
* [[Defibrotide]] | * [[Defibrotide]] | ||
| − | |||
| − | |||
* [[Protein C]] | * [[Protein C]] | ||
** [[Drotrecogin alfa]] | ** [[Drotrecogin alfa]] | ||
| + | * [[Ramatroban]] | ||
| + | * [[REG1<!--instantly reversible aptamer-based direct FIXa inhibitor in IIb trials -->]] | ||
}} | }} | ||
| − | | | + | | group3 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s |
| − | | | + | | list3 = |
* ''[[plasminogen activator]]s:'' ''[[recombinant tissue plasminogen activators|r-tPA]]'' | * ''[[plasminogen activator]]s:'' ''[[recombinant tissue plasminogen activators|r-tPA]]'' | ||
** [[Tissue plasminogen activator|Alteplase]] | ** [[Tissue plasminogen activator|Alteplase]] | ||
| Line 145: | Line 142: | ||
** [[Tenecteplase]] | ** [[Tenecteplase]] | ||
* ''UPA'' | * ''UPA'' | ||
| + | ** [[Saruplase]] | ||
** [[Urokinase]] | ** [[Urokinase]] | ||
| − | |||
| − | |||
* [[Anistreplase]] | * [[Anistreplase]] | ||
* [[Monteplase]] | * [[Monteplase]] | ||
| − | + | * [[Streptokinase]]<sup>#</sup> | |
*''other [[serine endopeptidase]]s:'' [[Ancrod]] | *''other [[serine endopeptidase]]s:'' [[Ancrod]] | ||
| + | * [[Brinase]] | ||
* [[Fibrinolysin]] | * [[Fibrinolysin]] | ||
| − | |||
| − | | | + | | group4 = [[Anticoagulant#Anticoagulants outside the body|Non-medicinal]] |
| − | | | + | | list4 = |
* [[Citrate]] | * [[Citrate]] | ||
| − | * [[EDTA]] | + | * [[Ethylenediaminetetraacetic acid|EDTA]] |
* [[Oxalate]] | * [[Oxalate]] | ||
| belowstyle = background: transparent; padding: 0px; | | belowstyle = background: transparent; padding: 0px; | ||
| − | | below = {{PharmNavFootnote}}{{Myeloid navs}} | + | | below = {{PharmNavFootnote}} {{Myeloid navs}} |
}}<noinclude> | }}<noinclude> | ||
[[Category:Antithrombotic agents]] | [[Category:Antithrombotic agents]] | ||
[[Category:Drug_templates by ATC]] | [[Category:Drug_templates by ATC]] | ||
| + | |||
[[hu:Sablon:Antitrombotikumok]] | [[hu:Sablon:Antitrombotikumok]] | ||
[[pt:Predefinição:Antitrombóticos]] | [[pt:Predefinição:Antitrombóticos]] | ||
[[zh:Template:抗血栓药]] | [[zh:Template:抗血栓药]] | ||
</noinclude> | </noinclude> | ||